S-1/A: Bicara Therapeutics Eyes Nasdaq Listing with $228.4 Million IPO to Advance Cancer Therapies

Bicara Therapeutics is seeking to raise $228.4 million through an IPO to fund the clinical development of its lead drug candidate, ficerafusp alfa, and expand its research into other solid tumors.

Summary

• Bicara Therapeutics, a clinical-stage biopharmaceutical company, is planning an initial public offering (IPO) to raise approximately $228.4 million.
• The company intends to use the IPO proceeds, along with existing cash, to advance the development of its lead program, ficerafusp alfa, particularly in head and neck squamous cell carcinoma (HNSCC).
• A significant portion of the funds will be allocated to a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy for recurrent/metastatic HNSCC, excluding HPV-positive patients.
• Bicara also plans to expand the development of ficerafusp alfa into additional HNSCC patient populations and other solid tumors, such as colorectal cancer and other squamous cell carcinomas.
• The company anticipates initiating the Phase 2/3 trial in late 2024 or early 2025, with an interim analysis for overall response rate (ORR) expected in 2027.
• The IPO involves offering 14,705,882 shares of common stock with an expected initial price between $16.00 and $18.00 per share.
• Underwriters have an option to purchase an additional 2,205,882 shares.
• The company has applied to list its common stock on The Nasdaq Global Market under the symbol BCAX.
• Bicara has raised $353 million since inception, including a $165 million Series C financing in December 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting promising clinical data and a clear development pathway. However, it also acknowledges the inherent risks and challenges associated with drug development and commercialization, resulting in a moderate sentiment score.

Positives

• Ficerafusp alfa has shown a 64% ORR in HPV-negative HNSCC patients in an ongoing Phase 1/1b trial when combined with pembrolizumab, suggesting potential as a first-line therapy.
• The company has a validated dual-targeting mechanism of action with the potential for potent and durable anti-tumor activity.
• The company is addressing a significant unmet need in HPV-negative R/M HNSCC with a clear development pathway.
• The company has a strong and experienced team with deep expertise in clinical development.

Negatives

• The company has a limited operating history and has incurred significant financial losses since its inception.
• The company is dependent on the success of ficerafusp alfa, and its business will be materially harmed if it is unable to successfully complete clinical development, obtain regulatory approval, or commercialize ficerafusp alfa.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable.
• Clinical development involves a lengthy and expensive process with uncertain outcomes.

Risks

• The company may require additional funding in order to finance operations, and if it is unable to raise capital when needed, or on acceptable terms, it could be forced to delay, reduce, or eliminate its product development programs or commercialization efforts.
• Ficerafusp alfa or any future product candidates may cause undesirable side effects or have other properties when used alone or in combination with other approved products or investigational new drugs that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.
• The commercial success of ficerafusp alfa or any future product candidates will depend upon the degree of market acceptance of such product candidates by physicians, patients, healthcare payors and others in the medical community.
• The company relies, and expects to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct its preclinical studies and clinical trials.
• The company currently and in the future may depend on other third-party collaborators for the discovery, development and commercialization of ficerafusp alfa and any of its future product candidates.

Future Outlook

The company anticipates initiating a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in late 2024 or early 2025 and projects that the ORR interim analysis may occur in 2027.

Management Comments

• The company aims to replicate Phase 1b data in a pivotal randomized Phase 2/3 trial.
• The company believes that ficerafusp alfa in combination with pembrolizumab has the potential to become a first-line standard of care therapy in HPV-negative R/M HNSCC.

Industry Context

The announcement comes amid intense competition in the biotechnology industry, particularly in the development of cancer therapies. Bicara is positioning itself to compete with established treatments like pembrolizumab and cetuximab, as well as emerging therapies from other companies.

Comparison to Industry Standards

• The historical response rate observed in a Phase 3 trial with pembrolizumab monotherapy, the current standard of care in R/M HNSCC, was 19%.
• Treatment with ficerafusp alfa in combination with pembrolizumab demonstrated an 18% (5/28) complete response rate, or CR rate, and a median progression-free survival, or mPFS, of 9.8 months in HPV-negative patients.
• The PFS benefit in historical published data for pembrolizumab monotherapy was 3.2 months in an HPV-negative and HPV-positive population, and the PFS benefit for cetuximab and anti-PD-1 combination ISTs was 6.2 to 6.5 months in an HPV-negative and HPV-positive population.

Related Party Transactions

• The company has entered into a Contract Transfer and License Agreement with Biocon Limited.
• The company has entered into a Clinical Trial Collaboration and Supply Agreement with MSD International GmbH and MSD International Business GmbH.
• The company has entered into a master services agreement with Biofusion Therapeutics Limited.
• The company has entered into a manufacturing agreement with Biocon Biologics Limited.
• The company has entered into a manufacturing agreement with Syngene International Limited.
• The company entered into a full recourse promissory note with Ivan Hyep, our Chief Financial Officer.
• The company has entered into an investors rights agreement, voting agreement and right of first refusal agreement with the purchasers of our preferred stock and certain holders of our common stock.

Stakeholder Impact

• The IPO is intended to create a public market for the company's common stock, which could benefit existing shareholders.
• The development of ficerafusp alfa could potentially provide a new treatment option for patients with solid tumors, particularly HNSCC.
• The company's growth and success could create new job opportunities and contribute to the local economy.

Next Steps

• Initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy in R/M HNSCC, excluding HPV-positive patients, late in the fourth quarter of 2024 or early in the first quarter of 2025.
• Conduct an interim analysis to determine if the ORR is sufficient to seek accelerated approval and continue the trial with the goal of demonstrating a statistically significant improvement in OS.
• Announce updated interim Phase 1/1b data at future medical meetings in 2025.
• Explore additional development opportunities to maximize the potential of ficerafusp alfa for the treatment of cancer.

Key Dates

Keywords

ficerafusp alfa, HNSCC, biopharmaceutical, clinical trial, EGFR, TGF-b, oncology, cancer, IPO